TrialSignal transduction and targeted therapy2026

Entinostat plus exemestane for hormone receptor-positive advanced breast cancer: long-term overall survival results from the EOC103A3101 randomized controlled trial.

Jiani Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.